Ann M.  Hanly net worth and biography

Ann Hanly Biography and Net Worth

Aine Hanly, Ph.D., serves as Chief Technology Officer at Vir Biotechnology, where she is responsible for overseeing the Company’s technical operations. Her purview includes product and process development, supply chain, manufacturing, quality and CMC strategy. Her career in the biomanufacturing industry, which has spanned roles in the UK, Ireland and the US, has been dedicated to advancing innovative solutions to accelerate the delivery of medicines to patients.

Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams enabling the commercialization of Amgen’s pipeline products as well as providing technical support for ongoing commercial manufacturing operations. Additionally, as site head at Amgen’s Cambridge facility, Dr. Hanly led the site’s transformation and staff growth, and together with the research and development team, greatly increased Amgen’s partnerships and presence within the local Cambridge ecosystem. She also worked for more than 10 years at Pfizer (formerly, Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, quality and product supply strategy.

Dr. Hanly received her bachelor’s degree in biological chemistry and a Ph.D. in physical organic chemistry, from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as lead scientist studying gene isolation and subsequent confirmation using a variety of molecular biology techniques.

What is Ann M. Hanly's net worth?

The estimated net worth of Ann M. Hanly is at least $1.36 million as of February 22nd, 2024. Dr. Hanly owns 134,780 shares of Vir Biotechnology stock worth more than $1,361,278 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Hanly may own. Additionally, Dr. Hanly receives an annual salary of $842,230.00 as CTO at Vir Biotechnology. Learn More about Ann M. Hanly's net worth.

How old is Ann M. Hanly?

Dr. Hanly is currently 53 years old. There are 5 older executives and no younger executives at Vir Biotechnology. Learn More on Ann M. Hanly's age.

What is Ann M. Hanly's salary?

As the CTO of Vir Biotechnology, Inc., Dr. Hanly earns $842,230.00 per year. Learn More on Ann M. Hanly's salary.

How do I contact Ann M. Hanly?

The corporate mailing address for Dr. Hanly and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Ann M. Hanly's contact information.

Has Ann M. Hanly been buying or selling shares of Vir Biotechnology?

Over the course of the past ninety days, Ann M. Hanly has sold $123,574.80 of Vir Biotechnology stock. Most recently, Ann M. Hanly sold 12,296 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $10.05, for a transaction totalling $123,574.80. Following the completion of the sale, the executive vice president now directly owns 134,780 shares of the company's stock, valued at $1,354,539. Learn More on Ann M. Hanly's trading history.

Who are Vir Biotechnology's active insiders?

Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.

Are insiders buying or selling shares of Vir Biotechnology?

In the last twelve months, insiders at the sold shares 29 times. They sold a total of 1,164,404 shares worth more than $28,983,591.36. The most recent insider tranaction occured on February, 26th when Director George A Scangos sold 17,722 shares worth more than $206,461.30. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.

Information on this page was last updated on 2/26/2024.

Ann M. Hanly Insider Trading History at Vir Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2024Sell12,296$10.05$123,574.80134,780View SEC Filing Icon  
3/30/2023Sell2,627$22.77$59,816.79114,576View SEC Filing Icon  
2/23/2023Sell2,302$25.97$59,782.94117,203View SEC Filing Icon  
3/30/2022Sell2,627$26.24$68,932.48View SEC Filing Icon  
11/29/2021Buy12$43.39$520.68View SEC Filing Icon  
See Full Table

Ann M. Hanly Buying and Selling Activity at Vir Biotechnology

This chart shows Ann M Hanly's buying and selling at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vir Biotechnology Company Overview

Vir Biotechnology logo
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $10.10
Low: $9.78
High: $10.24

50 Day Range

MA: $10.18
Low: $8.60
High: $11.90

2 Week Range

Now: $10.10
Low: $7.72
High: $27.48

Volume

995,068 shs

Average Volume

971,068 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42